Time Toxicity of Endocrine-based Oral CDK4/6 Inhibitor Therapies
Geburtshilfe und Frauenheilkunde · 01.01.2026 · 86 (01) · 65-74
DOI: 10.1055/a-2717-7930 ↗Kurz gefasst
Fachartikel in der Zeitschrift Geburtshilfe und Frauenheilkunde, erschienen am 01.01.2026. Verfasst von Henning Schäffler und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, University Clinic Ulm, Ulm, Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Adjuvant endocrine therapy with CDK4/6 inhibitors necessitates regular visits, lab assessments and side effect management, currently conducted primarily at breast cancer centers in Germany. This retrospective analysis estimates the potential travel distances, times and CO2 emissions associated with centralized therapy management of adjuvant CDK 4/6 inhibitor application.Eligible patients for ribociclib or abemaciclib therapy were retrospectively identified from 5053 early breast cancer cases at the university hospitals of Ulm, Lübeck and Tübingen, using the monarchE and NATALEE criteria. Travel times were calculated assuming 24 visits over three years for ribociclib and 18 visits over two years for abemaciclib.Of the HR+/HER2− cohort, 1432 (38%) were potentially eligible for adjuvant CDK4/6 inhibitors, with 1080 patients included, based on available postal codes. Median travel distances and times for Ribociclib (3 years) were 1200 km (24.0 hours driving; 176.0 kg CO2 emissions; 50.4 hours by public transport; 72.0 kg CO2 emissions) and 900 km (18.0 hours driving; 132.3 kg CO2 emissions; 37.8 hours by public transport; 54.0 kg CO2 emissions) for abemaciclib (2 years).Despite its retrospective limitations, this analysis provides valuable insight into the impact of centralized care on travel time and CO2 emissions for oral cancer therapies in Germany. As the use of oral therapies increases, clinicians, patients, policymakers and the pharmaceutical industry should jointly develop strategies to optimize the safety, feasibility, and efficacy of oral therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, University Clinic Ulm, Ulm, Germany.
- Department of Women's Health, Tuebingen University Hospital, Tübingen, Germany.
- Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
ORCID-Profile: Nikolas Tauber
Zitieren
APA
Schäffler, H., Heublein, S., Lichtblau, J., Wisniewski, L., Rack, B., Janni, W., Englisch, A., Englisch, J., Engler, T., Hartkopf, A., Brucker, S., Hilmer, L., Fick, F., Kohls, F., Banys-Paluchowski, M., Rody, A., Dannehl, D., & Tauber, N. (2026). Time Toxicity of Endocrine-based Oral CDK4/6 Inhibitor Therapies. Geburtshilfe und Frauenheilkunde, 86(01), 65-74. https://doi.org/10.1055/a-2717-7930
Vancouver
Schäffler H, Heublein S, Lichtblau J, Wisniewski L, Rack B, Janni W, et al. Time Toxicity of Endocrine-based Oral CDK4/6 Inhibitor Therapies. Geburtshilfe und Frauenheilkunde. 2026;86(01):65-74. doi:10.1055/a-2717-7930
BibTeX
@article{Schffler2026,
author = {Schäffler, Henning and Heublein, Sabine and Lichtblau, Julia and Wisniewski, Lisa and Rack, Brigitte and Janni, Wolfgang and Englisch, Alexander and Englisch, Johannes and Engler, Tobias and Hartkopf, Andreas and Brucker, Sara and Hilmer, Lisbeth and Fick, Franziska and Kohls, Fabian and Banys-Paluchowski, Maggie and Rody, Achim and Dannehl, Dominik and Tauber, Nikolas},
title = {Time Toxicity of Endocrine-based Oral CDK4/6 Inhibitor Therapies},
journal = {Geburtshilfe und Frauenheilkunde},
year = {2026},
volume = {86},
number = {01},
pages = {65--74},
doi = {10.1055/a-2717-7930}
}
EUVIMED